Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 71, Issue 3, 2004, Pages 171-176

  Yao, Jeffrey K ^a,b,c   Magan, Sharon ^a,c   Sonel, Ali F ^a   Gurklis, John A ^a,b   Sanders, Richard ^a   Reddy, Ravinder D ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; SEROTONIN;

ADULT; BIOLOGICAL MONITORING; CELL MEMBRANE; CHRONIC DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; ERYTHROCYTE; HUMAN; MALE; MENTAL PATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; EICOSAPENTAENOIC ACID; ERYTHROCYTE MEMBRANE; HUMANS; MALE; PLATELET AGGREGATION; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA; SEROTONIN;

EID: 3142636598     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2004.03.011     Document Type: Conference Paper

References (42)

1. Peet M., Laugharne J.D., Mellor J., Ramchand C.N. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot. Essent. Fatty Acids. 55:1996;71-75
2. Peet M., Brind J., Ramchand C.N., Shah S., Vankar G.K. Two double blind placebo-controlled pilot studies of eicosapentanoic acid in the treatment of schizophrenia. Schizophr. Res. 49:2001;243-251
3. Peet M., Horrobin D.F. E-E Multicentre Study Group, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatry Res. 36:2002;7-18
4. Puri B.K., Richardson A.J., Horrobin D.F., Easton T., Saeed N., Oatridge A., Hajnal J.V., Bydder G.M. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int. J. Clin. Pract. 54:2000;57-63
5. Richardson A.J., Easton T., Puri B.K. Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentanoic acid. Eur. Neuropsychopharm. 10:2000;189-193
6. Richardson A.J., cyhlarova E., Puri B.K. Clinical and biochemical fatty acid abnormalities in dyslexia, dyspraxia and schizotypy. an overview Peet M., Glen L., Horrobin D.F. Phospholipid Spectrum Disorders in Psychiatry and Neurology. 2nd Edition:2003;477-490 Marius Press, Lancashire, UK
7. Stordy B. Long-chain fatty acids in the management of dyslexia and dyspraxia. Peet M., Glen I., Horrobin D.F. Phospholipid Spectrum Disorder in Psychiatry. 1999;251-260 Marius Press, Lancashire, UK
8. Yao J.K. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. Peet M., Glen I., Horrobin D.F. Phospholipid Spectrum Disorders in Psychiatry and Neurology. 2nd Edition:2003;193-212 Marius Press, Lancashire, UK
9. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., Allen M. Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naive schizophrenics. Arch. Gen. Psychiatry. 48:1991;563-568
10. 13P nuclear magnetic resonance spectroscopy. neurodevelopment and schizophrenia Schizophr. Bull. 19:1993;35-53
11. Reddy R.D., Keshavan M.S. Phosphorus magnetic resonance spectroscopy. its utility in examing the membrane hypothesis of schizophrenia Prostaglands Leukot. Essent. Fatty Acids. 69:2003;401-405
12. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry. 30:1991;795-805
13. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42:2000;7-17
14. Yao J.K., van Kammen D.P., Gurklis J., Peters J.L. Platelet aggregation and dense granule secretion in schizophrenia. Psychiatry Res. 54:1994;13-24
15. McBride P.A., Anderson G.M., Hertzig M., Sweeney J.A., Kream J., Cohen D.J., Mann J.J. Serotonergic responsivity in male young adults with autistic disorder. Arch. Gen. Psychiatry. 46:1989;213-221
16. De Clerck F. The role of serotonin in thrombogenesis. Clin. Physiol. Biochem. 8(Suppl. 3):1990;40-49
17. Yao J.K., van Kammen D.P., Moss H.B., Sokulski D.E. A decreased serotonergic responsivity in platelets of drug-free schizophrenic patients. Psychiatry Res. 63:1996;123-132
18. Dodge J.T., Mitchell C., Hanahan D.J. The preparation and chemical characteristics of hemoglobin-free ghosts on human erythrocytes. Arch. Biochem. Biophys. 100:1963;119-130
19. Rose H.G., Oklander M. Improved procedure for the extraction of lipids from human erythrocytes. J. Lipid Res. 6:1995;428-431
20. Ichihara K., Shibahara A., Yamamoto K., Nakayama T. An improved method for rapid analysis of the fatty acids of glycerolipids. Lipids. 31:1996;535-539
21. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 13:1994;217-226
22. Crawford M.A., Sinclair A.J. Nutritional influence in the evolution of mammalian brain. Elliott K., Knight J. Lipids, Malnutrition and the Developing Brain, Ciba Foundation Symposia. Vol. 3:1972;267-287 Excerpta Medica, Amsterdam
23. Yao J.K., van Kammen D.P. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr. Res. 11:1994;209-216
24. Heron D., Shinitzky M., Hershkowitz M., Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membrane. Proc. Natl. Acad. Sci. USA. 77:1980;7463-7467
25. Hibbeln J.R., Salem N. Jr. Dietary polyunsaturated fatty acids and depression. Am. J. Clin. Nutr. 62:1995;1-9
26. Hibblen J.R., Umhau J.C., Linnoila M., George D.T., Regan P.W., Shoaf S.E., Vaughan M.R., Rawlings R., Salem N. Jr. A replication study of violent and nonviolent subjects. cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids Biol. Psychiatry. 44:1998;243-249
27. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Nuerotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry. 36:1979;927-934
28. 2) receptor binding in frontal cortex of schizophrenic patients. J. Neural Transm. Gen. Section. 85:1991;19-29
29. 2A receptor mRNAs and binding sites are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455
30. Dean B., Hayes W., Hill C., Copolov D. Decreased serotonin-2A receptors in Brodmann's area 9 from schophrenic subjects, a pathological or pharmacological phenomenon? Mol. Chem. Neuropathol. 34:1998;133-145
31. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia. a postmortem study Biol. Psychiatry. 42:1997;529-545
32. 2A receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Res. 96:2000;41-50
33. 2A receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients. Psychiatry Res. 118:2003;165-174
34. Ostrowitzki S., Rao M.L., Redei J., Andres A.H. Concurrence of cortex and platelet serotonin 2 receptor binding characteristics in the individual and the putative regulation by serotonin. J. Neural Transm. 93:1993;27-35
35. Garelis E., Gillin J., Wyatt R., Neff N. Elevated blood serotonin concentration in unmedicated chronic schizophrenic patients. Am. J. Psychiatry. 132:1975;184-186
36. DeLisi L.E., Neckers L.M., Weinberger D.R., Wyatt R. Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch. Gen. Psychiatry. 38:1981;647-650
37. Jackman H., Luchins D., Meltzer H.Y. Platelet serotonin levels in schizophrenia. relationship to race and psychopathology Biol. Psychiatry. 18:1983;887-902
38. Stahl S.M., Wood D.J., Mefford I.N., Berger P.A., Ciranello R.D. Hyperserotoninemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am. J. Psychiatry. 140:1983;26-30
39. Joseph M., Owen F., Baker H., Bourne R. Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and schizoaffective patients. Psychol. Med. 7:1977;159-162
40. Kolakowska T., Molyneux S.G. Platelet serotonin concentration in schizophrenic patients. Am. J. Psychiatry. 144:1987;232-234
41. Kristensen S.D., Schmidt E.B., Dyerberg J. Dietary supplementation with n-3 polyunsaturated fatty acids and human platelet function. a review with particular emphasis on implications for cardiovascular disease J. Internal Med. 225:1989;141-150
42. Hamberg M., Svensson J., Samuelsson B. Thromboxanes. a new group of biologically active compounds derived from prostaglandin endoperoxide Proc. Natl. Acad. Sci. USA. 72:1975;2994-2998